BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has appointed Charles A. Sanders, M.D. to the company's Board of Directors. Dr. Sanders has an extensive experience working as a corporate executive and director, physician and professor of medicine. Dr. Sanders is retired from Glaxo, Inc., where he held the position as CEO from 1989-1994 and Chairman of the Board of 1992-1995. He is a graduate of the University of Texas' Southwestern Medical College.
MicroCap Insider is a web-based financial portal that publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors. Sign Up for our Free Stock Newsletter
About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians.
